06:05 PM EDT, 10/21/2024 (MT Newswires) -- Editas Medicine ( EDIT ) and Genevant Sciences said Monday they will combine Editas' CRISPR Cas12a genome editing systems with Genevant's LNP technology in the development of in vivo gene editing medicines for two targets in Editas' upregulation strategy.

Genevant granted Editas a nonexclusive license to exploit mRNA-CRISPR Cas12a-LNP products for the targets, with Genevant eligible to receive up to $238 million in upfront and contingent milestone payments, according to the companies.

Price: 3.8100, Change: +0.05, Percent Change: +1.33